Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine Eye Drops for Myopia Progression
NCT06996236Phase 2Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of brimonidine in myopia. Primary endpoint: Effect of brimonidine eye drops 0.025% on myopia progression at 24 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
brimonidine
03
Conditions
myopia
Beyond the preview
Go deeper on NCT06996236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996236.